Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biotech company pioneering novel small molecule therapies for neurodegenerative diseases and rare genetic disorders through its proprietary computational drug discovery platform. This page serves as the definitive source for verified updates on clinical trials, research breakthroughs, and corporate developments.
Investors and researchers will find timely updates on the company’s lead candidate GT-02287 for Parkinson’s disease, along with pipeline progress across lysosomal storage disorders and oncology targets. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations – all essential for understanding GANX’s position in the competitive biopharmaceutical landscape.
Key updates cover three critical areas: clinical trial milestones for brain-penetrant therapies, advancements in AI-driven target identification via the Magellan platform, and strategic collaborations accelerating therapeutic development. Bookmark this page to track how GANX’s focus on allosteric modulation could reshape treatment paradigms.
Gain Therapeutics (NASDAQ: GANX) presented data at the 36th EORTC-NCI-AACR Symposium showcasing their allosteric inhibitor GT-03842, identified through their Magellan Drug Discovery Platform. The compound effectively targets and inhibits DDR2 phosphorylation, a protein associated with various cancer types and tumor progression. GT-03842 demonstrated dose-dependent inhibition in both HEK293 cells and a metastatic breast cancer model. The compound's unique mechanism, targeting outside the kinase domain, suggests potential advantages over traditional kinase inhibitors, including enhanced selectivity and reduced resistance.
Gain Therapeutics (Nasdaq: GANX) announced a poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The poster will showcase the use of Gain's Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors.
DDR2 is implicated in various cancer types and plays a important role in tumor progression. Allosteric small molecule inhibitors have the potential to overcome resistance and offer improved selectivity and safety compared to traditional kinase inhibitors. The presentation, titled 'Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)', will be given by Sara Cano-Crespo, Ph.D., from Gain Therapeutics during the Molecular Targeted Agents poster session on October 23, 2024, at 11am CEST.
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced that its Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., will present at the Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference on October 17, 2024, in New York City. The presentation will focus on the company's clinical stage lead drug candidate GT-02287, which is being developed for the treatment of Parkinson's disease.
Dr. Hannestad's oral presentation, titled 'Brain-penetrant small molecule GT-02287 is well-tolerated in healthy volunteers, shows GCase target engagement, and achieves therapeutic exposures shown to modulate PD pathobiology in preclinical models,' will be part of the conference's first session, 'Progress in the Therapeutics Pipeline.' The presentation will include Phase 1 data for GT-02287 and recent preclinical findings.
The Parkinson's Disease Therapeutics Conference is the only global event focused exclusively on Parkinson's disease drug development, bringing together 300 research and clinical development professionals from academia and industry to showcase innovative research from MJFF's portfolio.
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkinson's disease models
3. Reduction in Tau accumulation in GBA-1 mutation and wild type cell lines
The results suggest GT-02287's potential as a disease-modifying therapy for Parkinson's disease and possibly Alzheimer's disease and other tauopathies. The compound showed positive effects on mitochondrial and lysosomal health, addressing the disease cascade resulting from GCase dysfunction.
Gain Therapeutics, a clinical-stage biotechnology company, announced participation in two upcoming investor conferences. Gene Mack, interim CEO and CFO, will represent the company at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, engaging in one-on-one meetings and a panel on 'Emerging Frontiers in Neuroscience'. He will also attend the 2024 Maxim Healthcare Virtual Summit on October 15, participating in a fireside chat with Jason McCarthy, Ph.D., from Maxim Group. Interested attendees can sign up on M-Vest for updates.
Gain Therapeutics presented Phase 1 data for GT-02287, its lead drug candidate for Parkinson's disease, at the International Congress of Parkinson's Disease and Movement Disorders. The study demonstrated that GT-02287 was safe and well-tolerated in healthy volunteers, with no serious adverse events. Notably, the drug increased GCase activity by approximately 30% in subjects who received GT-02287, indicating target engagement. The drug also showed CNS exposure, with measurable levels in cerebrospinal fluid.
The company plans to initiate a trial in Parkinson's disease patients by the end of Q4 2024, aiming to demonstrate safety, tolerability, and obtain proof of mechanism based on relevant biomarkers. Gain Therapeutics remains optimistic about GT-02287's potential as a disease-modifying treatment for Parkinson's disease.
Gain Therapeutics (Nasdaq: GANX) announced a virtual webinar on September 30, 2024, at 8:30 am ET to discuss results from the Phase 1 study of GT-02287, their novel GCase-targeting small molecule therapy for Parkinson's disease. The company will present positive results recently shared at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) and outline the design of an upcoming Phase 1b trial in Parkinson's disease patients.
The webinar will include a live Q&A session following formal presentations. Interested parties can register for the event or join via the company's website. A replay will be available in the News and Events section of the Gain Therapeutics website after the event.
Gain Therapeutics (Nasdaq: GANX) announced three presentations at Neuroscience 2024, showcasing preclinical data for GT-02287, their lead drug candidate for Parkinson's disease. The event will be held in Chicago from October 5-9, 2024.
Two late-breaking posters will be presented:
- GT-02287's prevention of Tau accumulation in a cellular model
- GT-02287's disease-modifying capacity in both GBA1 and idiopathic Parkinson's disease models
A third presentation will focus on GT-02287's improvement of mitochondrial function and neuroprotective effects in GBA1-Parkinson's disease models. These studies were conducted in collaboration with researchers from Switzerland, supported by an Innosuisse-Swiss Innovation Agency grant.
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company focused on developing next-generation allosteric small molecule therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024.
Gene Mack, Interim CEO and CFO, and Dr. Jonas Hannestad, Chief Medical Officer, will represent Gain Therapeutics at the conference. They will deliver a corporate presentation and engage in one-on-one meetings with potential investors and partners.
This participation provides Gain Therapeutics with an opportunity to showcase its innovative approach to drug discovery and development, potentially attracting investor interest and fostering new collaborations in the biotechnology sector.
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease. The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at all dose levels, with no discontinuations or serious adverse events reported. Importantly, the drug showed presence in the cerebrospinal fluid and achieved peripheral target engagement.
Based on these promising results, Gain plans to initiate a Phase 1b trial in Parkinson's disease patients by Q4 2024, with data expected by mid-2025. The company aims to demonstrate safety, tolerability, and proof of mechanism through relevant biomarkers in this upcoming trial.
FAQ
What is the current stock price of Gain Therapeutics (GANX)?
What is the market cap of Gain Therapeutics (GANX)?
